Covid 19 Research using Clinical Trials (Home Page)
Report for D010034: Otitis Media with Effusion NIH
(Synonyms: Otitis Media with, Otitis Media with Effusion)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003638 | Deafness NIH | 1.00 |
| D034381 | Hearing Loss NIH | 1.00 |
| D006314 | Hearing Loss, Conductive NIH | 1.00 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0040262 | Glue ear HPO | 1.00 |
| HP:0000405 | Conductive hearing impairment HPO | 1.00 |
| HP:0000365 | Hearing impairment HPO | 0.71 |
There is one clinical trial.
Clinical Trials
1 Exploring Interventions for Children With Chronic Otitis Media With Effusion ('Glue Ear') When Services Are Reduced During Covid-19
During the Coronavirus pandemic children's hearing services are closed or reduced and grommet operations are part of the lowest priority group. In the absence of management options, this research study aims to see if bone conduction headphones either paired (via bluetooth) to a microphone or an app will help children with a hearing loss during this period of waiting. The child's quality of life is measured with validated questionnaires The study is over 3 months, and delivered remotely, with the product being sent to the family home and support offered via telephone/ video consulattion.
NCT04427631 Hearing Impaired Children Glue Ear Hearing Loss, Conductive Device: Bone conduction headphones MeSH:Hearing Loss Deafness Otitis Media with Effusion Hearing Loss, Conductive
HPO:Conductive hearing impairment Glue ear Hearing impairment
Primary Outcomes
Description: questionnaire based accpetability question. A higher acceptability score will be positive for the intervention.
Measure: acceptability of management strategy, questionnaire Time: Acceptability will be measured on a Likert scale pre-assessment and the end of 3 months of using the intervention
Secondary Outcomes
Description: validated questionnaire assessing quality of life in children with glue ear. The questionnaire assess disease- related hearing difficulty and treatment-related improvements in hearing. Improved (lower) scores will indicate a more positive response from the intervention.
Measure: quality of life questionnaire OMQ-14 Time: Questionnaires at beginning of study (as a baseline assessment and after 3 months of using the intervention. The sc
HPO Nodes
HP:0040262: Glue ear
Genes 47
DNAAF5 CCNO RPGR RSPH9 DNAJB13 RSPH1 STK36 SPEF2 CCDC40 SPAG1 DNAH9 FOXJ1 MCIDAS HYDIN ZMYND10 DNAAF6 OFD1 RSPH4A DNAH5 CCDC114 GAS2L2 CCDC103 LRRC56 DNAAF4 DNAH1 NME8 CCDC151 GAS8 TTC12 CCDC39 ARMC4 DNAL1 TTC25 DNAAF2 DNAI2 CCDC65 CFAP298 DNAAF3 DRC1 CFAP300 NEK10 CFAP221 RSPH3 LRRC6 DNAH11 DNAI1 DNAAF1 Protein Mutations 0
SNP 0
Primary Outcomes
Description: questionnaire based accpetability question. A higher acceptability score will be positive for the intervention.
Measure: acceptability of management strategy, questionnaire Time: Acceptability will be measured on a Likert scale pre-assessment and the end of 3 months of using the interventionSecondary Outcomes
Description: validated questionnaire assessing quality of life in children with glue ear. The questionnaire assess disease- related hearing difficulty and treatment-related improvements in hearing. Improved (lower) scores will indicate a more positive response from the intervention.
Measure: quality of life questionnaire OMQ-14 Time: Questionnaires at beginning of study (as a baseline assessment and after 3 months of using the intervention. The sc